Protected when completed

Date Submitted: 2025-09-30 13:00:05
Confirmation Number: 1994752
Template: CIHR Biosketch

Dr. Kelsie Thu

Correspondence language: English
Sex: Female
Date of Birth: 4/11
Canadian Residency Status: Canadian Citizen
Country of Citizenship: Canada

Contact Information

The primary information is denoted by (*)

Address

Primary Affiliation

Department of Laboratory Medicine and Pathobiology
University of Toronto
1 King's College Circle
Toronto Ontario M5S 1A8
Canada

Primary Affiliation (*)

LKSKI of St. Michael's Hospital
Keenan Research Centre for Biomedical Science
209 Victoria St
6th Floor, Office 611
Toronto Ontario M5B 1T8
Canada

Telephone

Work (*) 416-3604000 extension: 49890

Email

Work (*) kelsie.thu@unityhealth.to

Website

Personal http://stmichaelshospitalresearch.ca/researchers/kelsie-thu/

CIHR IRSC
Canadian Institutes of Health Research | Instituts de recherche en santé du Canada

Canadian Common CV commun canadien

Protected when completed

Dr. Kelsie Thu

Degrees

2015/5 - 2020/6	Post-doctorate, Cancer Biology and Therapeutic Response (Supervisor: Tak Mak), University Health Network Degree Status: Completed
2008/9 - 2013/11	Doctorate, Interdisciplinary Oncology (Supervisor: Wan Lam), University of British Columbia Degree Status: Completed
2002/9 - 2007/4	Bachelor's, Biological Sciences, Simon Fraser University Degree Status: Completed

Recognitions

2025/9 - 2030/8	Tier 2 Canada Research Chair in lung cancer therapy response (renewal) Government of Canada
2025/4	Outstanding Reviewer, College of Reviewers Canadian Institutes of Health Research
2022/5	Outstanding Reviewer, College of Reviewers Canadian Institutes of Health Research
2020/9 - 2025/8	Tier 2 Canada Research Chair in lung cancer therapy response Government of Canada
2019/9 - 2020/6	Scholarship for the Next Generation of Scientists Cancer Research Society

Employment

2020/7	Assistant Professor Laboratory Medicine and Pathobiology, Medicine, University of Toronto
2020/7	Scientist Keenan Research Centre for Biomedical Science, Li Ka Shing Knowledge Institute, St. Michael's Hospital
2015/5 - 2020/6	Postdoctoral Fellow (Supervisor: Tak Mak) Campbell Family Institute for Breast Cancer Research, Princess Margaret Cancer Centre, University Health Network
2018/9 - 2018/12	Teaching Assistant Biology, Science, University of Toronto at Mississauga

2016/9 - 2017/4	Teaching Assistant Medicine, St. George Campus, University of Toronto
2013/10 - 2015/4	Research Associate (Supervisor: Wan Lam) Integrative Oncology, BC Cancer Research Centre, British Columbia Cancer Agency

Affiliations

The primary affiliation is denoted by (*)

(*) 2020/7	Scientist, St. Michael's Hospital

Research Funding History

Awarded [n=11]

2025/3 - 2030/2
Principal Investigator

The role of extracellular vesicle (EV)-mediated crosstalk between cancer cells and platelets and in tumor progression

Funding Sources:
Canadian Foundation for Innovation (CFI) and Ontario Research Fund
John R. Evans Leaders Fund [INFRASTRUCTURE GRANT]
Total Funding - 2,000,000
Funding Competitive?: Yes

Co-investigator : Heyu Ni

2024/9 - 2029/8
Principal Investigator

Discovering pathways to drug tolerance and therapeutic vulnerabilities of persister cells in lung cancer

Funding Sources:
Canadian Institutes of Health Research (CIHR)
Project Grant ($250,000 to Thu Lab)
Total Funding - 1,292,850
Funding Competitive?: Yes

Principal Investigator : Ming Tsao

2025/4 - 2029/3
Co-investigator

Unlocking the Potential of Immune Checkpoint Inhibitors in the Papillary Renal Cell Carcinoma Setting

Funding Sources:
Department of Defense (USA)
Kidney Cancer Research Program Idea Development Award ($0 to Thu Lab)
Total Funding - 800,000
Funding Competitive?: Yes

2023/9 - 2028/8
Co-applicant

Aiming at a new target in endotoxin-associated lung damage: The Ig domain 3 of ICAM-1

Funding Sources:
Canadian Institutes of Health Research (CIHR)
Project Grant ($0 to Thu Lab)
Total Funding - 982,260
Funding Competitive?: Yes

Principal Investigator : Haibo Zhang

2025/5 - 2027/4
Principal Investigator

Using custom-engineered viruses to treat cancer

Funding Sources:
St. Michael's Hospital Foundation
Sarah McComb Award for Cancer Research

Total Funding - 120,000
Funding Competitive?: Yes

2024/9 - 2026/8
Principal Investigator

Enhancing CD47-targeted therapy in lung cancer with ultrasound and microbubbles

Funding Sources:
Cancer Research Society (The)
Operating Grant
Total Funding - 130,000
Funding Competitive?: Yes

Co-applicant : Warren Lee

2024/9 - 2026/8
Co-applicant

Exploring non-canonical functions of YAP and TAZ in lung cancer

Funding Sources:
Cancer Research Society (The)
Operating Grant ($0 to Thu Lab)
Total Funding - 130,000
Funding Competitive?: Yes

Principal Investigator : Andras Kapus

2021/9 - 2026/8
Principal Investigator

Investigation of centrosome amplification as a therapeutic vulnerability in lung cancer

Funding Sources:
Canadian Institutes of Health Research (CIHR)
Project Grant
Total Funding - 841,500
Funding Competitive?: Yes

Co-applicant : Ming Tsao

2021/8 - 2026/7
Co-applicant

Understanding the effects of ERK hyperactivation in cancer: implications for therapy

Funding Sources:
Canadian Institutes of Health Research (CIHR)
Project Grant ($0 to Thu Lab)
Total Funding - 956,250
Funding Competitive?: Yes

Principal Investigator : William Lockwood

2023/3 - 2026/2
Co-applicant

The problem of non-clear cell renal cell carcinoma; tailoring the treatment to the biology

Funding Sources:
Kidney Foundation of Canada (KFC)
Kidney Health Research Grant ($0 to Thu Lab)
Total Funding - 180,000
Funding Competitive?: Yes

Principal Investigator : Rola Saleeb

2023/12 - 2025/11
Co-applicant

Cancelling Chemo: An Alternative Treatment for Kidney Cancer

Funding Sources:
St. Michael's Foundation
Angel's Den ($0 to Thu Lab)
Total Funding - 100,000
Funding Competitive?: Yes

Co-applicant : Rola Saleeb

Completed [n=8]

2021/1 - 2025/12
Principal Investigator

Lung cancer therapy response

Funding Sources:
Canada Foundation for Innovation (CFI)
John R. Evans Leaders Fund [INFRASTRUCTURE GRANT]
Total Funding - 1,378,256
Funding Competitive?: Yes

2023/9 - 2025/8
Principal Investigator

Discovering novel strategies to enhance the efficacy of EGFR-targeted therapy in cancer

Funding Sources:
Unity Health Toronto Foundation
Cross Pillar Collaboration Seed Grant
Total Funding - 50,000
Funding Competitive?: Yes

Principal Investigator : Sunit Das

2024/9 - 2025/8
Principal Investigator

Using oncolytic virus to deliver CD47 blockade in lung cancer

Funding Sources:
JP Bickell Foundation
Medical Research Grant
Total Funding - 70,000
Funding Competitive?: Yes

2023/7 - 2024/6
Principal Investigator

Boosting antiviral signaling to improve the efficacy of chemotherapy

Funding Sources:
Unity Health Toronto Foundation
Sarah McComb Award, Finalist
Total Funding - 10,000
Funding Competitive?: Yes

Co-applicant : Andras Kapus; Katalin Szaszi

2020/9 - 2023/12
Principal Investigator

Understanding how lung tumours avoid destruction by the immune system

Funding Sources:
Cancer Research Society (The)
Next Generation of Scientists
Total Funding - 120,000
Funding Competitive?: Yes

2022/12 - 2023/11
Principal Investigator

Defining alterations in histone PTMs in never-smoker lung cancer

Funding Sources:
Lung Cancer Canada
Geoffrey Ogram Memorial Research Grant
Total Funding - 25,000
Funding Competitive?: Yes

Principal Investigator : Ju-Yoon Yoon

2020/7 - 2023/6
Principal Investigator

Lung cancer biology and therapy response

Funding Sources:
St. Michael's Hospital
Start Up Funds
Total Funding - 450,000
Funding Competitive?: Yes

2022/4 - 2023/3
Principal Investigator

Deciphering anti-PD1 sensitization mechanisms in lung cancer.

Funding Sources:
International Lung Cancer Foundation
Young Investigator Award
Total Funding - 50,000
Funding Competitive?: Yes

Publications

Journal Articles

1. Jajarmi J, Guest MR, Ma LJ, THU KL, Chari R, Lockwood WW. (2025). Pervasive mammalian promoter activity in E. coli affects representation of DNA encoded libraries. Communications Biology. -: -.
Revision Requested

2. Lau APY, Zhai LG, Wu YF, THU KL. (2025). CD47 regulates pro-metastatic phenotypes through an ERK-dependent epithelial-to-mesenchymal transition program in non-small cell lung cancer. Molecular Oncology. -: -.
Submitted
Refereed?: Yes, Open Access?: Yes

3. Abdelkader Y, Abdelkarim M, Suresh M, Lopera TJ, Dhaliwa S, Shojaei S, Pope LJ, Liu Q, Hu P, Guinta S, Haga H, THU KL, Ishihara S, Anikovskiy M, Labouta HI. (2025). Genomic Instability and Shear Stress as Determinants for Nanoparticle-Induced Endothelial Cell Responses and Gene Expression. Materials Today Nano. 31(August): 100641.
Published

4. Bhat V, THU KL, Bonvissuto AC, Ghasemi F, Goodale D, Roes M, Dick FA, Cescon DW, Allan AL, Parsyan A. (2025). Loss of Artemis (DCLRE1C) enhances radiotherapy response in triple-negative breast cancer through activation of cellular senescence. Cancers. -: -.
Revision Requested

5. Rousseau Z, Ma W, Long T, Slavkovic S, Qiu X, Lao X, Zhu Y, Zhu G, THU KL, Ni H. (2025). Platelet CLEC-2 Activation Leads to $GP1b\alpha$ Shedding: Implications for Doxorubicin Chemotherapy and Thrombosis. Journal of Biological Chemistry. -: -.
Revision Requested

6. Zhang C, Wu BZ, THU KL. (2025). Targeting Kinesins For Therapeutic Exploitation of Chromosomal Instability in Lung Cancer. Cancers. 17(4): 685.
Published
Refereed?: Yes, Open Access?: Yes

7. Hoshi R, Gorospe KA, Labouta HI, Azad T, Lee WL, THU KL. (2024). Alternative strategies for delivering immunotherapeutics targeting the PD-1/PD-L1 immune checkpoint in cancer. Pharmaceutics. 16(9): 1181.
Published
Refereed?: Yes

8. Zhang CZ, Wu BZ, Wu YF, Khavkine Binstock SS, Di Ciano-Oliveira C, Soria-Bretones I, Pham NA, Elia AJ, Chari R, Lam WL, Bray MR, Mak TW, Tsao MS, Cescon DW, THU KL. (2024). Identification of KIFC1 as a putative vulnerability in lung cancers with centrosome amplification. Cancer Gene Therapy. 10(-): 1559-1570.
Published
Refereed?: Yes

9. Wang D, Cheung A, Mawdsley GE, Liu K, Yerofeyeva Y, THU KL, Yoon JY, Jaffe MJ. (2024). A modified bleaching method for multiplex immunofluorescence staining of FFPE tissue sections. Applied Immunohistochemistry & Molecular Morphology. 32(10): 447-452.
Published

10. THU KL, Yoon JYY. (2024). ATM - The Gene At The Moment in Non-small Cell Lung Cancer. Translational Lung Cancer Research. 13(3): 699-705.
Published
Refereed?: Yes

11. Liu W, Mousa AAK, Hopkins AM, Wu YF, THU KL, Campbell M, Lees SJ, Ramachandran R, Hou J. (2024). Lysophosphatidic acid receptor 1 (LPA1) antagonists as potential migrastatics for triple negative breast cancer. ChemMedChem. 19(16): e202400013.
Submitted
Refereed?: Yes

12. Lau APY, Khavkine Binstock SS, THU KL. (2023). CD47: The next frontier in immune checkpoint blockade for non-small cell lung cancer. Cancers. 15(21): 5229.
Published
Refereed?: Yes, Open Access?: Yes

13. Soria-Bretones I, THU KL, Silvester J, Cruickshank J, Ba-Alawi W, Elliott MJ, Chalmers J, Elia A, Cheng A, Fletcher GC, Kiarash R, Haibe-Kains B, Rose A, Bray MR, Mak TW, Cescon DW. (2022). The spindle assembly checkpoint is a therapeutic vulnerability of CDK4/6 inhibitor-resistant ER+ breast cancer. Science Advances. Sep 9;8(36):eabq4293: doi: 10.1126/sciadv..
Published
Refereed?: Yes

14. Joshi K, Sanwal R, THU KL, Tsai SSH, Lee WL. (2022). Plug & Pop: A 3D-Printed, Modular Platform forDrug Delivery using Clinical Ultrasound and Microbubbles. Pharmaceutics. 14(11): 2516.
Published
Refereed?: Yes

15. Chan CY, Chiu DK, Yuen VW, Law CT, Wong BP, THU KL, Cescon DW, Soria-Bretones I, Cheu JW, Lee D, Tse AP, Zhang MS, Tan KV, Ng IO, Khong P, Yau TC, Bray MR, Mak TW, Wong CC. (2022). CFI-402257, a TTK inhibitor, effectively suppresses hepatocellular carcinoma. Proceedings of the National Academy of Sciences. 119(32):e2119514119: doi: 10.1073/pnas.21.
Published
Refereed?: Yes

16. Chan CY, Yuen VW, Chiu DK, Goh CC, THU KL, Cescon DW, Soria-Bretones I, Law CK, Cheu JW, Lee D, Tse AP, Tan KV, Zhang MS, Wong BP, Khong PL, Ng IO, Yau TC, Bray MR, Mak TW, Wong CC. (2022). Polo-like kinase 4inhibitor CFI-400945 suppresses liver cancer through cell cycle perturbationand eliciting antitumor immunity. Hepatology. ahead of print: doi: 10.1002/hep.324.
Published
Refereed?: Yes

17. O'Farrell H, Harbourne B, Kurlawala Z, Inoue Y, Nagelberg A, Martinez VD, Lu D, Oh MH, Coe BP, THU KL, Somwar R, Lam S, Lam WL, Unni AM, Beverly L, Lockwood WW. (2019). Integrative genomic analyses identifies GGA2 as a cooperative driver of EGFR-mediated lung tumorigenesis. Journal of Thoracic Oncology. 14(4): 656-671.
Published
Refereed?: Yes

18. Kubli SP, Bassi C, Roux C, Wakeham A, Gobl C, Zhou W, Jafari SM, Snow B, Jones L, Palomero L, THU KL, Cassetta L, Soong D, Berger T, Ramachandran P, Baniasadi SP, Duncan G, Lindzen M, Yarden Y, Herranz C, Lazaro C, Chu MF, Haight J, Tinto P, Silvester JS*, Cescon DW, Petit A, Pettersson S, Pollard JW, Mak TW, Pujana MA, Cappello P, Gorrini C. (2019). AhR controls redox homeostasis and shapes the tumor microenvironment in BRCA1-associated breast cancer. Proceedings of the National Academy of Sciences of the United States of America. 116(9): 3604-3613.
Published
Refereed?: Yes

19. Zheng L, Chen Z, Kawakami M, Chen Y, Roszik J, Mustachio LM, Kurie JM, Villalobos PA, Lu W, Behren CM, Mino B, Solis LM, Silvester J*, THU KL, Cescon DW, Rodriguez-Canales J, Wistuba II, Mak TW, Liu X, Dmitrovsky E. (2019). Tyrosine threonine kinase inhibition eliminates lung cancers by augmenting apoptosis and aneuploidy. Molecular Cancer Therapeutics. 18(10): 1775-1786.
Published
Refereed?: Yes

20. THU KL, Silvester J*, Elliott MJ*, Ba-alawi W, Duncan MH*, Elia AC*, Mer AS, Smirnov P, Safikhani Z, Haibe-Kains B, Mak TW, Cescon DW. (2018). Disruption of the anaphase-promoting complex confers resistance to TTK inhibitors in triple-negative breast cancer. Proceedings of the National Academy of Sciences of the United States of America. 115(7): E1570-E1577.
Published
Refereed?: Yes

21. Kawakami M, Mustachio LM, Zheng L, Chen Y, Rodriguez-Canales J, Mino B, Kurie JM, Roszik J, Villalobos PA, THU KL, Silvester J*, Cescon DW, Wistuba II, Mak TW, Liu X, Dmitrovsky E. (2018). Reply to Oegema et al.: CFI-400945 and Polo-like kinase 4 inhibition. Proceedings of the National Academy of Sciences of the United States of America. 115(46): E10810-E10811.
Published
Refereed?: No

22. Kawakami M, Mustachio LM, Zheng L, Chen Y, Rodriguez-Canales J, Mino B, Kurie JM, Roszik J, Villalobos PA, THU KL, Silvester J*, Cescon DW, Wistuba II, Mak TW, Liu X, Dmitrovsky E. (2018). Polo-like kinase 4 inhibition produces polyploidy and apoptotic death of lung cancers. Proceedings of the National Academy of Sciences of the United States of America. 115(8): 1913-1918.
Published
Refereed?: Yes

23. Elliott MJ*, Jerzak KJ, Cockburn JG, Safikhani Z, Gwynne WD, Hassell JA, Bane A, Silvester J*, THU KL, Habie-Kains B, Mak TW, Cescon D. (2018). The Antiarrhythmic Drug, Dronedarone, Demonstrates Cytotoxic Effects in Breast Cancer Independent of Thyroid Hormone Receptor Alpha 1 ($THR\alpha1$) Antagonism. Scientific Reports. 8(16562): 1-10.
Published
Refereed?: Yes

24. THU KL, Soria-Bretones I*, Mak TW, Cescon DW. (2018). Targeting the cell cycle in breast cancer: towards the next phase. Cell Cycle. 17(15): 1871-1885.
Published
Refereed?: Yes

Book Chapters

1. Thu KL, Cescon DW, and Hakem R. (2021). Chapter 8: Cell Proliferation and Death. David W Cescon, Ian F. Tannock, Richard P. Hill, Robert G. Bristow, Lea Harrington. The Basic Science of Oncology. 6th: 1-30. Published, McGraw-Hill International Editions, United States of America

Conference Publications

1. Gorospe KA, Li M, Arivajiagane A, Pham NA, Navab R, THU KL, Tsao MS. In vitro and in vivo modelling of drug tolerance and minimal residual disease to discover effective therapeutic combination strategies for EGFR-mutated lung cancer. American Association for Cancer Research, Chicago, United States of America
   Conference Date: 2025/4
   Abstract
2. Lau APY, THU KL. Upregulation of PD-L1 as a mechanism of resistance to CD47 inhibition in non-small cell lung cancer. American Association for Cancer Research Special Conference on Tumor Immunology and Immunotherapy, Boston, United States of America
   Conference Date: 2024/10
   Abstract
   Refereed?: Yes
3. Khavkine Binstock SS, Zou K, Wu YF, Kapus A, THU KL. Suppression of chemotherapy induced antiviral signaling by YAP/TAZ in lung cancer. International Association for the Study of Lung Cancer World Conference on Lung Cancer, San Diego, United States of America
   Conference Date: 2024/9
   Abstract
   Refereed?: Yes
4. Hoshi R, Lau A, Joshi K, Sanwal R, Hysi R, Lee W, THU K. Optimizing delivery of anti-cancer therapeutics in lung adenocarcinoma using ultrasound-induced cavitation of microbubbles. International Association for the Study of Lung Cancer World Conference on Lung Cancer, San Diego, United States of America
   Conference Date: 2024/9
   Abstract
   Refereed?: Yes
5. Lau A, Hoshi R, Rousseau Z, Wu YF, Ni H, THU KL. CD47 promotes migration and metastasis in non-small cell lung cancer. International Association for the Study of Lung Cancer World Conference on Lung Cancer, San Diego, United States of America
   Conference Date: 2024/9
   Abstract
   Refereed?: Yes
6. Zhang C, Wu BZ, Wu YF, Di Ciano-Oliveira C, Yoon JY, Mak TW, Cescon DW, THU KL. KIFC1 is a therapeutic target in lung cancers with extra centrosomes. American Association for Cancer Research Annual Meeting, Orlando, United States of America
   Conference Date: 2023/4
   Abstract
   Refereed?: Yes
7. Lau APY, Kubli SP, Wakeham A, Mak TW, THU KL. CD47 is a promising therapeutic target in non-small cell lung cancer. American Association for Cancer Research Annual Meeting, Orlando, United States of America
   Conference Date: 2023/4
   Abstract
   Refereed?: Yes
8. Zhang CZ, Wu BZ, Di Ciano-Oliveira C, Li Q, Weiss J, Pham N-A, Lam WL, Tsao MS, Yoon J-Y, THU KL. Centrosome amplification is a prognostic indicator and potential therapeutic vulnerability in non-small cell lung cancer. International Association for the Study of Lung Cancer World Conference on Lung Cancer, Vienna, Austria
   Conference Date: 2022/8
   Abstract
   Refereed?: Yes, Invited?: No

9. Lau APY, Kubli SP, Wakeham AC, Mak TW, THU KL. CD47 inhibition impairs the growth of orthotopic, immune competent lung tumour models. International Association for the Study of Lung Cancer World Conference on Lung Cancer, Vienna, Austria
Conference Date: 2022/8
Abstract
Refereed?: Yes, Invited?: No

10. THU KL, Kubli SP, Wakeham AC, Elia AJ, Mak TW. Development of an in vivo platform to identify novel mechanisms governing lung cancer response to immunotherapy. International Association for the Study of Lung Cancer World Conference on Lung Cancer, Barcelona, Spain
Conference Date: 2019/9
Abstract
Refereed?: Yes, Invited?: Yes

11. Bretones IS*, THU KL, Silvester J*, Kiarash R, Fletcher GC, Cruickshank J, Bray MR, Mak TW and Cescon DW. CDK4/6 inhibitor-resistant ER+ breast cancer cell lines are hypersensitive to TTK inhibition. San Antonio Breast Cancer Symposium, San Antionio, United States of America
Conference Date: 2019/1
Abstract
Refereed?: Yes, Invited?: Yes

Presentations

1. (2025). Unleashing the therapeutic potential of CD47 blockade in lung cancer. Cancer Research Center of Lyon Seminar Series, France
Main Audience: Researcher
Invited?: Yes, Keynote?: No

2. (2025). Exploring the therapeutic potential of CD47-targeted therapy in lung cancer. University of Leeds Visiting Speaker Seminars, United Kingdom
Main Audience: Researcher
Invited?: Yes, Keynote?: No

3. (2024). Identifying vulnerabilities associated with centrosome amplification in lung cancer. Bellairs Symposium on Genome Engineering and Repair, Barbados
Main Audience: Researcher
Invited?: Yes, Keynote?: No

4. (2023). Investigating KIFC1 as a therapeutic target in lung cancers with centrosome amplification. University of Otago UOC Research Seminar Series, New Zealand
Main Audience: Researcher
Invited?: Yes, Keynote?: No

5. (2022). Investigating centrosome amplification as a therapeutic vulnerability in lung cancer. Laboratory Medicine and Pathobiology Faculty Seminar, University of Toronto, Canada
Main Audience: Researcher
Invited?: Yes, Keynote?: No

Student/Postdoctoral Supervision

Bachelor's [n=4]

2025/5 - 2025/8 Principal Supervisor	Aiman Nawaid, Unity Health Toronto Thesis/Project Title: Investigating the Role of YAP/TAZ in Spindle Assembly Checkpoint Regulation Present Position: BSc Candidate, McMaster University
2025/5 - 2025/8 Principal Supervisor	Chiara Oliveira, Unity Health Toronto Thesis/Project Title: Investigating oncolytic viruses as a vehicle for delivering CD47 blockade in murine models of lung cancer Present Position: BSc Candidate Waterloo University
2024/9 Principal Supervisor	Ethan Ortiz, University of Toronto Thesis/Project Title: *Characterizing drug tolerant persister cells in lung cancer* Present Position: BSc, Laboratory Medicine and Pathobiology
2024/5 Principal Supervisor	Patrick Wang, University of Toronto Thesis/Project Title: *Investigating the role of YAP/TAZ in lung cancer chemoresistance* Present Position: BSc Candidate, Laboratory Medicine and Pathobiology

Doctorate [n=6]

2024/9 Co-Supervisor	Kangni Zou, University of Toronto Thesis/Project Title: Deciphering the role of YAP/TAZ in spindle assembly checkpoint regulation Present Position: PhD candidate, Laboratory Medicine and Pathobiology
2023/9 Co-Supervisor	Kristyna Gorospe, University of Toronto Thesis/Project Title: Characterizing drug tolerant persister cells and their therapeutic vulnerabilities in EGFR-driven lung cancer Present Position: PhD, University of Toronto, Laboratory Medicine and Pathobiology
2022/9 Co-Supervisor	Sharon Khavkine-Binstock, University of Toronto Thesis/Project Title: The role of YAP/TAZ in lung cancer chemoresistance. Present Position: MSc, University of Toronto, Laboratory Medicine and Pathobiology
2022/9 Co-Supervisor	Ryunosuke Hoshi, University of Toronto Thesis/Project Title: Developing an innovative method to delivery CD47-targeted immunotherapy in lung cancer. Present Position: PhD, University of Toronto, Laboratory Medicine and Pathobiology
2021/9 - 2023/8 Principal Supervisor	Christopher Zhang, University of Toronto Thesis/Project Title: Targeting centrosome amplification in lung cancer Present Position: MSc, Laboratory Medicine and Pathobiology
2021/8 - 2023/8 Principal Supervisor	Asa Lau, University of Toronto Thesis/Project Title: Characterizing innate immune checkpoint inhibitors in lung cancer Present Position: MSc, Laboratory Medicine and Pathobiology